PSA and follow-up after treatment of prostate cancer;PSA et suivi après traitement du cancer de la prostate

Progres en Urologie

Volumn 18, Issue 3, 2008, Pages 137-144

  Benchikh El Fegoun, A ^a   Villers, A ^a   Moreau, J L ^b   Richaud, P ^c   Rebillard, X ^d   Beuzeboc, P ^e  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b University Hospital and Nancy University   (France)

^c INSTITUT BERGONIÉ   (France)

^d Clinique Beausoleil   (France)

^e INSTITUT CURIE   (France)

Author keywords

Definition of biochemical recurrence; Lowering of PSA; Modalities and frequency of PSA assay

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; HUMAN; MALE; METASTASIS; PATIENT CARE; PROSTATE TUMOR; PROSTATECTOMY; SHORT SURVEY; TUMOR RECURRENCE;

CHEMOTHERAPY, ADJUVANT; CONTINUITY OF PATIENT CARE; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; TUMOR MARKERS, BIOLOGICAL;

EID: 43049118595     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2007.12.010     Document Type: Short Survey

References (68)

1. Patel A., Dorey F., Franklin J., and deKernion J.B. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol 158 (1997) 1441-1445
2. Richaud P., Moreau J.L., Beuzeboc P., Rebillard X., Villers A., Peyromaure M., et al. Follow-up of prostate cancer. Guidelines of the comite de cancerologie de l'Association française d'urologie. Prog Urol 15 (2005) 586-592
3. Haese A., Huland E., Graefen M., Hammerer P., Noldus J., and Huland H. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol 161 (1999) 1206-1211
4. Stamey T.A., Graves H.C., Wehner N., Ferrari M., and Freiha F.S. Early detection of residual prostate cancer after radical prostatectomy by an ultrasensitive assay for prostate specific antigen. J Urol 149 (1993) 787-792
5. Shen S., Lepor H., Yaffee R., and Taneja S.S. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J Urol 173 (2005) 777-780
6. Ellis W.J., Vessella R.L., Noteboom J.L., Lange P.H., Wolfert R.L., and Rittenhouse H.G. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. Urology 50 (1997) 573-579
7. Yu H., Diamandis E.P., Wong P.Y., Nam R., and Trachtenberg J. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0. 1 microG/L. J Urol 157 (1997) 913-918
8. Aus G., Abrahamsson P.A., Ahlgren G., Hugosson J., Lundberg S., Schain M., et al. Hormonal treatment before radical prostatectomy: a three-year followup. J Urol 159 (1998) 2013-2016 [discussion 16-7]
9. Pound C.R., Partin A.W., Epstein J.I., and Walsh P.C. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24 (1997) 395-406
10. Schild S.E., Wong W.W., Novicki D.E., Ferrigni R.G., and Swanson S.K. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay. Urology 47 (1996) 878-881
11. Freedland S.J., Sutter M.E., Dorey F., and Aronson W.J. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61 (2003) 365-369
12. Amling C.L., Bergstralh E.J., Blute M.L., Slezak J.M., and Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol 165 (2001) 1146-1151
13. Stephenson A.J., Kattan M.W., Eastham J.A., Dotan Z.A., Bianco F.J.J., Lilja H., et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 24 (2006) 3973-3978
14. Pazona J.F., Han M., Hawkins S.A., Roehl K.A., and Catalona W.J. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates. J Urol 174 (2005) 1282-1286
15. Hull G.W., Rabbani F., Abbas F., Wheeler T.M., Kattan M.W., and Scardino P.T. Cancer control with radical prostatectomy alone in 1000 consecutive patients. J Urol 167 (2002) 528-534
16. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
17. Critz F.A., Williams W.H., Benton J.B., Levinson A.K., Holladay C.T., and Holladay D.A. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 163 (2000) 1085-1089
18. Rosser C.J., Kuban D.A., Levy L.B., Chichakli R., Pollack A., Lee A.K., et al. Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer. J Urol 168 (2002) 2001-2005
19. Hanlon A.L., Pinover W.H., Horwitz E.M., and Hanks G.E. Patterns and fate of PSA bouncing following 3D-CRT. Int J Radiat Oncol Biol Phys 50 (2001) 845-849
20. Shipley W.U., Thames H.D., Sandler H.M., Hanks G.E., Zietman A.L., Perez C.A., et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281 (1999) 1598-1604
21. Crook J.M., Choan E., Perry G.A., Robertson S., and Esche B.A. Serum prostate-specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure. Urology 51 (1998) 566-572
22. Hanlon A.L., Diratzouian H., and Hanks G.E. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 297-303
23. Swanson G.P., Riggs M.W., and Earle J.D. Long-term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 406-411
24. Gray C.L., Powell C.R., Riffenburgh R.H., and Johnstone P.A. Twenty-year outcome of patients with T1-3N0 surgically staged prostate cancer treated with external beam radiation therapy. J Urol 166 (2001) 116-118
25. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37 (1997) 1035-1041
26. Scher H.I., Eisenberger M., D'Amico A.V., Halabi S., Small E.J., Morris M., et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22 (2004) 537-556
27. Roach M.R., Hanks G.E., Thames H.J., Schellhammer P., Shipley W., Sokol G., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
28. Deger S., Boehmer D., Turk I., Roigas J., Wernecke K.D., Wiegel T., et al. High dose rate brachytherapy of localized prostate cancer. Eur Urol 41 (2002) 420-426
29. Poissonnier L., Gelet A., Chapelon J.Y., Bouvier R., Rouviere O., Pangaud C., et al. Results of transrectal focused ultrasound for the treatment of localized prostate cancer (120 patients with PSA< or +10 ng/ml. Prog Urol 13 (2003) 60-72
30. Vallancien G., Prapotnich D., Cathelineau X., Baumert H., and Rozet F. Transrectal focused ultrasound combined with transurethral resection of the prostate for the treatment of localized prostate cancer: feasibility study. J Urol 171 (2004) 2265-2267
31. Gelet A., Chapelon J.Y., Poissonnier L., Bouvier R., Rouviere O., Curiel L., et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 63 (2004) 625-629
32. Chodak G.W., Thisted R.A., Gerber G.S., Johansson J.E., Adolfsson J., Jones G.W., et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 330 (1994) 242-248
33. Johansson J.E., Adami H.O., Andersson S.O., Bergstrom R., Holmberg L., and Krusemo U.B. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 267 (1992) 2191-2196
34. Steinberg G.D., Bales G.T., and Brendler C.B. An analysis of watchful waiting for clinically localized prostate cancer. J Urol 159 (1998) 1431-1436
35. Soulie M., Barre C., Beuzeboc P., Chautard D., Cornud F., Eschwege P., et al. Prostatic cancer. Prog Urol 14 (2004) 913 15-55
36. Carter H.B., and Pearson J.D. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am 20 (1993) 665-670
37. Kattan M.W., Eastham J.A., Wheeler T.M., Maru N., Scardino P.T., Erbersdobler A., et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 170 (2003) 1792-1797
38. Klotz L. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer. Nat Clin Pract Urol 2 (2005) 136-142 [quiz 1 p following 49]
39. Kishi H., Igawa M., Kikuno N., Yoshino T., Urakami S., and Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171 (2004) 1855-1860
40. Pollack A., Zagars G.K., el-Naggar A.K., and Terry N.H. Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer. Urology 44 (1994) 711-718
41. Arai Y., Okubo K., Terada N., Matsuta Y., Egawa S., Kuwao S., et al. Volume-weighted mean nuclear volume predicts tumor biology of clinically organ-confined prostate cancer. Prostate 46 (2001) 134-141
42. Stephenson A.J., Aprikian A.G., Souhami L., Behlouli H., Jacobson A.I., Begin L.R., et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology 59 (2002) 652-656
43. Smith Jr. J.A., Lange P.H., Janknegt R.A., Abbou C.C., and deGery A. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. J Urol 157 (1997) 1329-1334
44. Small E.J., McMillan A., Meyer M., Chen L., Slichenmyer W.J., Lenehan P.F., et al. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points and survival. J Clin Oncol 19 (2001) 1304-1311
45. Terris M.K., Klonecke A.S., McDougall I.R., and Stamey T.A. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. J Nucl Med 32 (1991) 1713-1717
46. Miller J.I., Ahmann F.R., Drach G.W., Emerson S.S., and Bottaccini M.R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147 (1992) 956-961
47. Crook J.M., Szumacher E., Malone S., Huan S., and Segal R. Intermittent androgen suppression in the management of prostate cancer. Urology 53 (1999) 530-534
48. Kurek R., Renneberg H., Lubben G., Kienle E., and Tunn U.W. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35 Suppl. 1 (1999) 27-31
49. Prapotnich D., Fizazi K., Escudier B., Mombet A., Cathala N., and Vallancien G. A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 43 (2003) 233-239 [discussion 39-40]
50. Schmid H.P., McNeal J.E., and Stamey T.A. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 71 (1993) 2031-2040
51. Zelefsky M.J., Ben-Porat L., Scher H.I., Chan H.M., Fearn P.A., Fuks Z.Y., et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol 23 (2005) 826-831
52. Rogers C.G., Khan M.A., Craig Miller M., Veltri R.W., and Partin A.W. Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. Cancer 101 (2004) 2549-2556
53. Albertsen P.C., Hanley J.A., Penson D.F., and Fine J. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol 171 (2004) 2221-2225
54. Zhou P., Chen M.H., McLeod D., Carroll P.R., Moul J.W., and D'Amico A.V. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Clin Oncol 23 (2005) 6992-6998
55. Zagars G.K., and Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol 44 (1997) 213-221
56. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., and Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 20 (2002) 4567-4573
57. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172 (2004) S42-S46 [discussion S46-7]
58. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., and Blute M.L. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172 (2004) 2244-2248
59. Cannon Jr. G.M., Walsh P.C., Partin A.W., and Pound C.R. Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. Urology 62 Suppl. 1 (2003) 2-8
60. Partin A.W., Pearson J.D., Landis P.K., Carter H.B., Pound C.R., Clemens J.Q., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43 (1994) 649-659
61. Trapasso J.G., deKernion J.B., Smith R.B., and Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152 (1994) 1821-1825
62. Cher M.L., Bianco Jr. F.J., Lam J.S., Davis L.P., Grignon D.J., Sakr W.A., et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol 160 (1998) 1387-1391
63. Okotie O.T., Aronson W.J., Wieder J.A., Liao Y., Dorey F., De K.J., et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 171 (2004) 2260-2264
64. Sylvester J., Grimm P., Blasco J., Meier R., Spiegel J., Heaney C., et al. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: a survey of practice patterns of urologists and radiation oncologists in the United States. Urology 58 (2001) 65-70
65. Kelly W.K., and Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149 (1993) 607-609
66. Smith D.C., Dunn R.L., Strawderman M.S., and Pienta K.J. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer. J Clin Oncol 16 (1998) 1835-1843
67. Bubley G.J., Carducci M.A., Dahut W., Dawson N., Daliani D., Eisenberger M., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
68. D'Amico A.V. Radiation therapy for prostate cancer. In: Walsh P.C., Retik A.B., Vaughn E.D., and Wein A.J. (Eds). Campbell's Urology. (2002), Saunders, W.B, Philadelphia